# Acid Suppression {#id}

Mechanism of Action

|Property|Omeprazole|Ranitidine
|--|--|
|**Class**|Proton Pump Inhibitor|H<sub>2</sub>-receptor antagonist
|**Uses**|PUD, Zollinger-Ellison syndrome, NSAID-associated ulcers|As PPI
|**Presentation**|
|**Route of Administration**|PO/IV|PO/IV
|**Dosing**|20-40mg daily to BD|50mg TDS IV, 150mg BD PO
|**Absorption**|High PO bioavailability|50% PO bioavailability
|**Distribution**|95% protein bound, low V<sub>D</sub> of 0.3 L.kg<sup>-1</sup>|15% protein bound
|**Metabolism**|Prodrug, activated within parietal cell. CYP450 metabolised, inhibits CYP2C19 (reducing, among other things, the antiplatelet effect of clopidogrel)|Minimal hepatic
|**Elimination**|Faecal|Renal of active drug
|**Mechanism of Action**|Irreversibly blocks the K<sup>+</sup>/H<sup>+</sup> ATPase in parietal cells|Competitively antagonises H<sub>2</sub> receptors, which decreases the action of gastrin and ACh on parietal cells
|**Resp**||May increase incidence of VAP
|**Renal**|Interstitial nephritis
|**GIT**|↓ Acidity and volume of gastric secretions|↓ Acidity and volume of gastric secretions

---
##References
Peck and Hill
Smith, Scarth, Sasada